Keywords: Agenus, Oncophage, Antigenics, ChemRar, NewVac

Agenus out-licenses Russian rights to cancer vaccine

Article | 20 December 2011

Print This

US biotech firm Agenus (Nasdaq: AGEN), known as Antigenics until January of this year, has entered into a license, development ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in